A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for mental health.
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
Better Life Pharma reports encouraging pre-clinical results for its non-hallucinogenic psychedelic analog.
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada's SAP.
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder
Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.
Psychedelics Convergence in 2022: Crisis Meets Opportunity
The Mental Health Crisis spirals. Psychedelic medicine advances. In 2022, "crisis" meets "opportunity".
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
Health Canada’s SAP Amendments: A Game-Changer For Psychedelic Medicine In Canada?
On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.
